Are Options Traders Bullish on ADAP?
Let daily Option Order Flow show you where stock investors are Bullish and Bearish!!! Receive a FREE daily email of the Market Chameleon Order Flow Sentiment Newsletter.
Market Chameleon
Adaptimmune Therapeutics PLC American...





Please Login or Register

Login|Register FREE

Please Login or Register

Login|Register FREE

Stock Price
Open: 10.93
Prev. Close: 10.98
Low/Hi: 10.36 - 10.95
52-Week: 4.82 - 14.63
Equity: 331,074
90-Day Avg: 543,403
Option: 19
90-Day Avg: 183
Todays Stock Vol: 81.1
20-Day (HV): 46.9
52-Week (HV): 66.0
30-Day IV: 91.5 +8.6
IV Pct Rank: 96% Elevated
Div. Yield:
Earnings: 7-Aug (Est.)
P/E Ratio:
Market Cap: 1.0 B
Short Int Pct: 0.0%
Pct Held By Inst.: 59.1%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

About ADAP

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the bodys own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmunes lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. As of June 30, 2015, 85 patients had been treated with Adaptimmunes NY-ESO TCR therapeutic: 47 under Adaptimmunes IND, and 38 under a National Cancer Institute IND. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The Company currently has over 150 employees.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ADAP is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ADRD Invesco BLDRS Developed Markets 100 ADR Index Fund 64.9 M 6.49E+07 88 88 0.02% 0.00015 10 K 10123
ADRU Invesco BLDRS Europe Select ADR Index Fund 16.6 M 1.66E+07 76 76 0.02% 0.00019 3 K 3130
BIB ProShares Ultra Nasdaq Biotechnology 367.9 M 3.6791E+08 203 203 0.03% 0.000316951 257 K 257009
IBB iShares Nasdaq Biotechnology Index Fund 9.6 B 9.59496E+09 192 192 0.09% 0.0009 8.5 M 8474970
UBIO Proshares UltraPro Nasdaq Biotechnology 33.1 M 3.30685E+07 197 197 0.01% 0.000141721 16 K 16141

Wait, Before You Leave...